Immune Design (NASDAQ:IMDZ) released its quarterly earnings results on Wednesday. The biotechnology company reported ($0.29) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.39) by $0.10, Bloomberg Earnings reports. Immune Design had a negative return on equity of 68.69% and a negative net margin of 619.62%. The company had revenue of $0.49 million for the quarter, compared to analyst estimates of $0.81 million.
Immune Design (IMDZ) traded down $0.30 during trading on Thursday, reaching $3.70. The company’s stock had a trading volume of 712,117 shares, compared to its average volume of 542,153. Immune Design has a twelve month low of $2.80 and a twelve month high of $13.05. The company has a market capitalization of $189.83, a P/E ratio of -1.82 and a beta of 2.10.
In related news, major shareholder Leo Guthart bought 20,000 shares of the company’s stock in a transaction on Monday, January 8th. The shares were acquired at an average cost of $3.90 per share, with a total value of $78,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Carlos V. Paya sold 7,970 shares of the business’s stock in a transaction on Friday, January 5th. The stock was sold at an average price of $4.17, for a total value of $33,234.90. Following the completion of the sale, the chief executive officer now directly owns 114,560 shares in the company, valued at $477,715.20. The disclosure for this sale can be found here. Insiders sold 13,959 shares of company stock worth $58,209 over the last three months. Corporate insiders own 20.70% of the company’s stock.
Several research firms recently weighed in on IMDZ. Zacks Investment Research lowered Immune Design from a “buy” rating to a “hold” rating in a research report on Monday. Jefferies Group reissued a “buy” rating and issued a $8.00 target price on shares of Immune Design in a report on Thursday. Finally, Cowen reissued a “buy” rating on shares of Immune Design in a report on Monday, December 11th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $10.63.
COPYRIGHT VIOLATION NOTICE: This piece was originally reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://sportsperspectives.com/2018/03/14/immune-design-imdz-announces-quarterly-earnings-results-beats-estimates-by-0-11-eps.html.
About Immune Design
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.